Fundraising Archives

meat alternatives solar foods impossible foods

News and Trends 24 Mar 2021

Global Funding for Meat Alternative Companies Tripled in 2020

Companies developing sustainable meat and dairy alternatives smashed records with a €2.6B ($3.1B) haul last year. Why has it been such a bumper harvest? Traditional agriculture is a major polluter, especially in the case of meat production. The highest estimations place its share of global greenhouse gas emissions at up to 20%. In an effort […]

March 24, 2021 - 7 minutesmins - By Jonathan Smith

Interview 21 May 2020

What 2019 Can Teach About European Biotech Investments Going Forward

Following 2018’s bumper harvest for equity funding in European biotech, 2019 proved even more lucrative, particularly for private biotech companies. What are the biggest investment lessons learned from 2019, and how could Covid-19 change the dynamic in 2020? With the coronavirus pandemic thrusting global industry sectors into chaos, investors and entrepreneurs need to understand the […]

May 21, 2020 - 9 minutesmins - By Jonathan Smith

Expert Advice 6 Apr 2020

How Investors Can Prepare for the Digitization of Biotech

For a few decades, the worlds of biotech and digital technology have been on separate paths. Franck Lescure, Partner at the French VC firm Elaia Partners, explains how the two fields are now colliding and how investors need to catch up. At first glance, digital technology and biotech are widely different fields, each with their […]

April 6, 2020 - 6 minutesmins - By Jonathan Smith

News and Trends 14 Feb 2020

Italian Investment Firm AurorA Science Launches to Support Early Stage Biotechs

Italian technology transfer company AurorA-TT has joined forces with drug discovery companies Rottapharm Biotech and Italfarmaco to launch the biotech investment enterprise AurorA Science to support early stage biotechs. The partnership plans to invest €1–5M in each of one or two European start-ups this year. It is particularly focusing on promising biotechs in any area […]

February 14, 2020 - 2 minutesmins - By Laura Cowen

In Depth 11 Feb 2020

Why European Biotechs Should Look to China for Investment

Traditionally European biotechs have looked to the US for additional investment, but changes in the law and significant economic success in the country in recent years means that new opportunities are opening up in China that are ripe for exploitation. China has a massive population and a correspondingly large patient group. Homegrown science is pretty […]

February 11, 2020 - 8 minutesmins - By Helen Albert

Expert Advice 15 Jan 2020

How to Spot a Biotech Winner: Investment Lessons from Sofinnova

Making one biotech a success is hard enough, but correctly predicting multiple winners is the bread and butter of Antoine Papiernik, Managing Partner of Sofinnova Partners, one of the biggest and most prosperous life science venture capital investors in Europe. Papiernik began his career in corporate finance. In 1995, he was working in investment in […]

January 15, 2020 - 10 minutesmins - By Helen Albert

Interview 8 Oct 2019

Biotech Hubs: A Tale of Two Cities

Life science investors differ widely across biotech hubs in Europe. At Labiotech’s recent Refresh event, two investors from Cambridge and Paris compared the progress of these hubs and discussed the challenges that need to be overcome in biotech investment. Funding is the lifeblood of early biotech startups, and investors are a crucial supplier. For this […]

October 8, 2019 - 6 minutesmins - By Jonathan Smith

Opinion 30 Sep 2019

Can European Biotech Companies Afford Not to Work with China?

In the current trade standoff between the US and China, Europe has a golden opportunity to gain a competitive advantage. At every healthcare conference I’ve been to recently in the US or Europe, the same question is being debated on panels: Should you or should you not have a China strategy as a biotech CEO? […]

September 30, 2019 - 4 minutesmins - By Antoine Papiernik

Opinion 16 Jul 2019

The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting […]

July 16, 2019 - 5 minutesmins - By Antoine Papiernik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us